Ivermectin and Multiple Sclerosis: Current Evidence
Established Treatments and Safety Considerations
- Ivermectin is FDA-approved only for parasitic infections, with no proven therapeutic utility for neurological or autoimmune conditions, according to the FDA 1
- The American College of Physicians and other medical societies likely support the use of established disease-modifying therapies for MS treatment, as ivermectin has not been proven effective for this condition 2
- Higher doses of ivermectin may cause significant adverse effects, including dizziness, nausea, fever, headache, muscle/joint pain, and skin reactions, with a 2.5-fold increase in bioavailability when taken with high-fat food 4
- Patients with severe liver disease face a higher toxicity risk when taking ivermectin, and should be closely monitored 4
- The National Institute for Health and Care Excellence and other reputable guideline societies recommend using established disease-modifying therapies with proven efficacy in reducing relapse rates and disease progression in MS patients, rather than unproven treatments like ivermectin 5